# An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

> **NCT00538109** · NA · COMPLETED · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 8 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic

## Interventions

- **DRUG:** Glivec®/Gleevec®

## Key facts

- **NCT ID:** NCT00538109
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538109, "An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00538109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*